Could Adjuvant Chemotherapy after Surgery Benefit Elderly Patients with Advanced Gastric Cancer?
| Autor: | Seung Wan Ryu, In Gyu Kwon, Jin Woon Jeong, Young-Gil Son |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
medicine.medical_specialty Multivariate analysis medicine.medical_treatment Stomach neoplasms 03 medical and health sciences 0302 clinical medicine Gastrectomy Medicine Chemotherapy 030212 general & internal medicine Adverse effect Pathological Adjuvant Aged business.industry Gastroenterology Cancer Advanced gastric cancer medicine.disease Surgery Oncology 030220 oncology & carcinogenesis Original Article business |
| Zdroj: | Journal of Gastric Cancer |
| ISSN: | 2093-5641 2093-582X |
| Popis: | PURPOSE The aim of this study was to evaluate tolerance to adjuvant chemotherapy, and to compare survival between treatments using only surgery and using surgery with adjuvant chemotherapy, in elderly patients with advanced gastric cancer who were ≥75 years of age. MATERIALS AND METHODS Patients ≥75 years of age who were diagnosed with pathological stage II or III gastric cancer were identified retrospectively and categorized into the surgery only and surgery with adjuvant chemotherapy groups. Clinicopathological and survival data were compared between these two groups. RESULTS Among the 130 patients studied, 67 patients underwent curative surgery only, and 63 patients received adjuvant chemotherapy after curative surgery. In the latter group, adverse events were reported in 24 patients (38.1%). The treatments were discontinued in 19 patients (30.2%) owing to any reason. The overall 5-year survival rates of the surgery only and the surgery with adjuvant chemotherapy groups did not differ significantly (44.1% vs. 30.7%, respectively; P=0.804). Among 90 death events, deaths from recurrences of gastric cancer occurred in 42 patients. Multivariate analyses revealed that the American Society of Anesthesiologists score and the depths of tumor invasions were related to survival, and the addition of adjuvant chemotherapy after surgery did not influence survival. CONCLUSIONS The decision for the addition of adjuvant chemotherapy for elderly patients should be taken after considering the condition of individual patients and their life expectancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|